Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid
Status:
NOT_YET_RECRUITING
Trial end date:
2028-05-08
Target enrollment:
Participant gender:
Summary
This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Stapokibart in subjects with Moderate to Severe Bullous Pemphigoid.